Table 1. . EGFR–TKI versus conventional chemotherapy in NSCLC harboring mutated EGFR.
| Study | n (EGFRm+) | RR (%) | Median PFS (months) | Median OS (months) | Ref. |
|---|---|---|---|---|---|
| IPASS | 261 | 71.2 vs 47.3 | 9.5 vs 6.3 | 21.6 vs 21.9 | [2] |
| First-SIGNAL | 42 | 84.6 vs 37.5 | 8.0 vs 6.3 | 27.2 vs 25.6 | [3] |
| WJTOG 3405 | 172 | 62.1 vs 32.2 | 9.2 vs 6.3 | 34.8 vs 37.3 | [4] |
| NEJGSG002 | 228 | 73.7 vs 30.7 | 10.8 vs 5.4 | 27.7 vs 26.6 | [5] |
| OPTIMAL | 154 | 83 vs 36 | 13.1 vs 4.6 | 28.8 vs 22.7 | [6] |
| EURTAC | 173 | 58 vs 15 | 9.7 vs 5.2 | 28.6 vs 22.1 | [7] |
| LUX LUNG-3 | 345 | 56 vs 23 | 11.1 vs 6.9 | 28.2 vs 28.2 | [8] |
| LUX LUNG-6 | 364 | 66.9 vs 23.0 | 11.0 vs 5.6 | 23.1 vs 23.5 | [9] |
m: mutation; OS: Overall survival; PFS: Progression-free survival; RR: Response rate.